Durvalumab‐induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment
| Autor: | Kang Yun Lee, Woan Ruoh Lee, Yi Hsien Shih, Wei Hsi Lin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Durvalumab medicine.drug_class Dermatology Monoclonal antibody 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Neoplasms Psoriasis medicine Humans Adverse effect business.industry Antibodies Monoclonal General Medicine medicine.disease Rash Psoriasiform drug eruption 030220 oncology & carcinogenesis Concomitant Ultraviolet Therapy Methotrexate Drug Eruptions medicine.symptom business medicine.drug |
| Zdroj: | The Journal of Dermatology. 47:1041-1045 |
| ISSN: | 1346-8138 0385-2407 |
| DOI: | 10.1111/1346-8138.15371 |
| Popis: | Immune checkpoint inhibitors, including anti-programmed death 1 and anti-programmed death ligand 1, have become prominent treatment options for various types of cancers. However, immune checkpoint inhibitors are associated with various cutaneous adverse events, one of which is psoriasiform drug eruption. Some cases of psoriasiform drug eruption can only be controlled through the cessation of immune checkpoint inhibitors and administration of systemic immunosuppressants, such as corticosteroids and methotrexate. However, no clear guideline is available on the management of this specific rash, and the use of systemic immunosuppressants is contraindicated in selected conditions. In this article, we report a case of annular psoriasiform drug eruption induced by an anti-programmed death ligand 1 monoclonal antibody, durvalumab. The patient responded well to the combination of phototherapy and topical treatment, which allowed continuation of durvalumab treatment without concomitant systemic immunosuppressants in a 2-year follow up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text